PhaseBio Pharmaceuticals — Corporate Update (August 2019)
15 slides from PhaseBio Pharmaceuticals's corporate update, Aug 14, 2019
Slide 1: End of Phase 1 Meeting Update
End of Phase 1 Meeting Update August 14, 2019 Exhibit 99.1
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”)
Slide 3: PB2452 Highlights
PB2452, a novel reversal agent for Brilinta® (ticagrelor), provided immediate and sustained reversal of ticagrelor’s antiplatelet effects in a Phase 1 trial PB2452 received Breakthrough Therapy designation from FDA (May 2019) Reversal agent availability would further differentiate ticagrelor from ot
Slide 4: FDA agreed Accelerated Approval pathway appropriate for PB2452
FDA has agreed that Accelerated Approval pathway is the appropriate regulatory pathway for PB2452 Single, non-randomized, open label Phase 3 trial in both surgical and major bleeding populations planned to support a Biologics License Application (BLA) BLA submission for Accelerated Approval to inclu
Slide 5: PB2452 - Novel reversal agent for ticagrelor
PB2452 - Novel reversal agent for ticagrelor Human monoclonal antibody fragment (Fab), delivered intravenously in the hospital Phase 1 Proof of Concept Trial completed Selected for late-breaking oral presentation American College of Cardiology’s Annual Scientific Session (March 17, 2019) Simultaneou
Slide 6: PB2452: Well-Characterized Mechanism of Reversal of Ticagrelor
PB2452: Well-Characterized Mechanism of Reversal of Ticagrelor ADP ADP Platelet ADP binds to P2Y12 receptor causing platelet aggregation Ticagrelor binds to P2Y12, inhibiting ADP-induced platelet aggregation This is a reversible process with ticagrelor cycling on/off the P2Y12 receptors PB2452:ticag
Slide 7: Clinical Studies: BLA enabling data and trial timelines
Clinical Studies BLA enabling data Clinical Trial Timelines Phase 2a testing additional reversal regimen to cover 180 mg BID (2x recommended dose) in healthy older and elderly subjects on DAPT Trial will be completed Q4 2019, not required to finish prior to Phase 2b Phase 2b expected to start Q4 201
Slide 8: Phase 1 trial design and dosing cohorts
Cohort Ticagrelor Pretreatment PB2452 IV regimen Volunteers Active:Placebo 1 None 0.1 g 30 min 3A:1P 2 None 0.3 g 30 min 3A:1P 3 None 1 g 30 min 3A:1P 4 180 mg PO + 90 mg BID x 2 days 1 g 30 min 6A:2P 5 180 mg PO + 90 mg BID x 2 days 3 g 30 min 6A:2P 6 180 mg PO + 90 mg BID x 2 days 9 g 30 min 6A:2P
Slide 9: Treatment-Emergent Serious Adverse Events in Phase 1 Trial
Preferred Term All Placebo (N=16) n (%) All PB2452 (N=48) n (%) Total Number of SAEs 0 2 PB2452-related SAEs 0 0 Unrelated SAEs* 0 2 (4.2) Alcohol intoxication 0 1 (2.1) Acute Respiratory Failure 0 1 (2.1) *Both SAEs occurred in the same individual 4 days after discharge from the clinical site Treat
Slide 10: Treatment-Emergent Adverse Events
Treatment-Emergent Adverse Events Preferred Term All Placebo (N=16) n (%) All PB2452 (N=48) n (%) Total Number of TEAEs 3 27 Number of volunteers with at Least 1 TEAE 2 (12.5) 17 (35.4) Infusion site bruising 0 4 (8.3) Medical device site reaction 0 3 (6.3) Infusion site extravasation 0 2 (4.2) Vess
Slide 11: Onset and Duration of Ticagrelor Reversal – VerifyNow PRUTest
P<0.001 across all timepoints, Bonferroni adjusted Immediate and sustained reversal with bolus + prolonged infusion of 18 g PB2452 Complete reversal was observed 5 min after initiation of infusion Duration was infusion-time dependent, lasting 20-24 hours with a 16-hour infusion Onset and Duration of
Slide 12: Normalized Platelet Function After Ticagrelor Reversal
PRU= Platelet Reactivity Units Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. N Engl J Med 2019;Mar 17:[Epub ahead of print]. Presented by Dr. Deepak L. Bhatt at the American College of Cardiology Annual Scientific Session (ACC 2019), New Orlea
Slide 13: Phase 2a Trial Preliminary Results (First Cohorts)
Phase 2a Trial Preliminary Results (First 2 Cohorts) PB2452 exhibited immediate and sustained reversal in healthy older (50-64) and elderly (65-80) subjects on DAPT Statistically significant reversal at 5 minutes, sustained for over 20 hours, in total population and subgroups by age Complete reversa
Slide 14: PB2452 Program Summary and Next Steps
PB2452 Program Summary and Next Steps Product profile: Immediate and sustained reversal of ticagrelor antiplatelet effects Major bleeding and urgent surgical scenarios require immediate and sustained reversal Duration of reversal dependent on infusion length Clinically important immediate and sustai
Slide 15: Slide 15
PhaseBio Pharmaceuticals — Corporate Update (August 2019) on 6ix